Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Medigene AG. (9/26/16). "Press Release: Medigene Participates at Five National and International Conferences". Martinsried.

Organisation Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
Products Product TCR engineered T-cells
  Product 2 conference
Persons Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
  Person 2 Lemus, Dave (Proteros 201712– COO + CFO before Medigene + Sigma-Tau Pharmaceuticals + MorphoSys)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming national and international scientific, investor and business development conferences:

OktoberINVESTfest, 5th Annual Investors Conference

Date: 28 September 2016
Location: New York, USA
Dave Lemus, Medigene's COO, will give a company presentation.

Adoptive T-Cell Therapy Summit

Date: 10 - 11 October 2016
Location: London, UK
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk on the topic: "Mind the gap and fill the need: TCR cell therapies for patients with different MHCs and diverse forms of cancer."

Osaka Partnering / BioJapan 2016

Date: 11 - 14 October 2016
Location: Osaka and Yokohama, Japan

Forum Gesundheitsindustrie Baden-Württemberg

Date: 13 October 2016
Location: Heidelberg, Germany
Dr. Dr. Olav Zilian, Medigenes SVP Corporate Development
will give a talk on the topic: "Innovative T-cell therapy with Medigene's TCR platform ".

6. Equity Forum 2016 on Cancer Immunotherapy

Date: 26 October 2016
Location: Heilbronn, Germany
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will hold a presentation on the latest developments in the field of immunotherapies.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,

Record changed: 2017-07-02


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSBNL] – The Business Web Portal 600x86px

» top